Antidiabetic sulfonylureas and cAMP cooperatively activate Epac2A

Area of Science:

• Biochemistry
• Pharmacology
• Endocrinology

Background:

• Sulfonylureas are key drugs for managing type 2 diabetes by addressing insulin deficiency.
• These drugs target pancreatic β cell potassium channels and also interact with Epac2A, a protein that promotes insulin secretion via Rap1 activation.

Purpose of the Study:

• To identify the specific amino acid residues in Epac2A responsible for sulfonylurea binding.
• To elucidate the mechanism by which sulfonylureas activate Epac2A and influence insulin secretion.

Main Methods:

• Molecular docking simulations to predict binding sites.
• Site-directed mutagenesis to alter identified residues.
• Fluorescence resonance energy transfer (FRET) biosensor assays and direct binding experiments to assess drug interaction and protein activation.

Main Results:

• Identified specific amino acid residues in the cNBD-A domain of Epac2A critical for sulfonylurea interaction.
• Confirmed these residues' importance through mutagenesis, showing they are required for sulfonylurea binding and Rap1 activation.
• Demonstrated cooperative activation of Epac2A by sulfonylureas (binding cNBD-A) and cAMP (binding cNBD-B).

Conclusions:

• Sulfonylureas stabilize Epac2A in an active conformation through specific residue interactions.
• Findings provide crucial insights for designing novel Epac2A-targeting drugs for diabetes treatment.